The common strategy for making bispecific antibodies (BsAbs) involves combining the variable domains of the desired monoclonal antibodies (mAbs) into a single bispecific structure. Bispecific immunotherapeutics has generated many different formats of BsAbs including chemical heteroconjugation of two complete molecules or fragments of monoclonal antibodies, quadroma, F(ab)2, diabodies, tandem diabodies, and single-chain antibodies (scFv). This chapter describes the process of generating activated T cells and arming T cells with heteroconjugated BsAbs to target cancer cells.
CITATION STYLE
Thakur, A., Lum, L. G., & Mittal, S. (2018). Bispecific antibody armed T cells to target cancer cells. In Methods in Molecular Biology (Vol. 1722, pp. 117–126). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7553-2_8
Mendeley helps you to discover research relevant for your work.